Matinas BioPharma Receives Additional NYSE Notice Of Non-Compliance; Compliance Plan Accepted

Matinas BioPharma received an additional NYSE American notice on June 24, 2026 saying it is not in compliance with continued listing standards. The update signals ongoing listing risk and adds pressure on the stock, though the article provides no details on the specific deficiency or any immediate delisting action. The news is company-specific and likely a modest negative for shares.

Analysis

Matinas BioPharma received an additional NYSE American notice on June 24, 2026 saying it is not in compliance with continued listing standards. The update signals ongoing listing risk and adds pressure on the stock, though the article provides no details on the specific deficiency or any immediate delisting action. The news is company-specific and likely a modest negative for shares.